Overview of Dr. Mellinghoff
Dr. Ingo Mellinghoff is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Cancer Center. He received his medical degree from Technical University Munich Faculty of Medicine and has been in practice 24 years. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
160 East 53rd Street
New York, NY 10022
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2004- UCLA David Geffen School of Medicine/UCLA Medical CenterChief Residency, Internal Medicine, 1998 - 1999
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1995 - 1998
Technical University Munich Faculty of MedicineClass of 1993
Certifications & Licensure
NH State Medical License 2024 - 2026
CA State Medical License 1997 - 2025
NY State Medical License 2008 - 2025
Awards, Honors, & Recognition
- Member (elected) Association of American Physicians, 2020
- Member (elected) American Society of Clinical Investigation, 2013
Clinical Trials
- EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas Start of enrollment: 2011 Jan 07
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma Start of enrollment: 2011 Sep 01
Publications & Presentations
PubMed
- 206 citationsPhase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.Michael Lim, Michael Weller, Ahmed Idbaih, Joachim Steinbach, Gaetano Finocchiaro
Neuro-Oncology. 2022-11-02 - 877 citationsNeoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla, Willy Hugo, Alexander Lee
Nature Medicine. 2019-02-11 - 2481 citationsTumor mutational load predicts survival after immunotherapy across multiple cancer types.Robert M. Samstein, Chung-Han Lee, Alexander N. Shoushtari, Matthew D. Hellmann, Ronglai Shen
Nature Genetics. 2019-01-14
Abstracts/Posters
- Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)Ingo K Mellinghoff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.2019 ASCO Annual Meeting - 6/1/2019
- Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Press Mentions
Health Canada Approves First and Only Oral Treatment for Brain CancerOctober 22nd, 2024- IU Researcher Leads National Work Focused on Developing Treatments for Inherited Childhood CancersNovember 18th, 2021
- Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia’s Paxalisib and Kintara’s VAL-083 in GBM AGILE TrialJanuary 6th, 2021
- Join now to see all
Professional Memberships
- Member
- American Association for Cancer Research - AACRMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
